Repaglinide

Repaglinide (0.5 mg, 1 mg, 2 mg) is an oral carbamoylmethylbenzoic acid meglitinide analogue on the WHO Model List of Essential Medicines. It acts as a rapid-onset, short-acting prandial insulin secretagogue by closing ATP-sensitive potassium channels on pancreatic beta-cell membranes via a distinct binding site from sulfonylureas. Features rapid absorption and ultra-short elimination half-life (around 1 hour), allowing "one meal, one dose; no meal, no dose" flexibility. Indicated for type 2 diabetes mellitus, particularly in patients with irregular meal schedules or prominent postprandial hyperglycemia.

Repaglinide (0.5 mg, 1 mg, 2 mg) is an oral carbamoylmethylbenzoic acid meglitinide analogue on the WHO Model List of Essential Medicines. It acts as a rapid-onset, short-acting prandial insulin secretagogue by closing ATP-sensitive potassium channels on pancreatic beta-cell membranes via a distinct binding site from sulfonylureas. Features rapid absorption and ultra-short elimination half-life (around 1 hour), allowing "one meal, one dose; no meal, no dose" flexibility. Indicated for type 2 diabetes mellitus, particularly in patients with irregular meal schedules or prominent postprandial hyperglycemia.

Repaglinide (0.5 mg, 1 mg, 2 mg) is an oral carbamoylmethylbenzoic acid meglitinide analogue on the WHO Model List of Essential Medicines. It acts as a rapid-onset, short-acting prandial insulin secretagogue by closing ATP-sensitive potassium channels on pancreatic beta-cell membranes via a distinct binding site from sulfonylureas. Features rapid absorption and ultra-short elimination half-life (around 1 hour), allowing "one meal, one dose; no meal, no dose" flexibility. Indicated for type 2 diabetes mellitus, particularly in patients with irregular meal schedules or prominent postprandial hyperglycemia.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.